TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Co-Infection
Research conducted at W. Manosuthi and co-authors has provided new information about HIV/AIDS co-infection
May 27th, 2008
According to a study from Nonthaburi, Thailand, " There is limited comparative data between efavirenz (EFV) 600 mg/day and nevirapine (NVP) 400 mg/day-based antiretroviral therapy (ART) among HIV-1 patients with tuberculosis (TB) and receiving rifampicin. A retrospective cohort study was conducted in all ART-naive patients who were receiving rifampicin between January 2002 and December 2005." " Of 188 patients, 77 and 111 patients were initiated on EFV-based ART (EFV group) and NVP-based ART (NVP group), respectively. Overall, median [interquartile range (IQR)] CD4 count was 36 (15-77) cells/mu L and median (IQR) viral load was 5.6 (5.2-5.9) HIV-1 RNA log copies/mL. At...
Source: TB & Outbreaks Week (2008-05-27)
|
